MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance
A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease.
Clinical trials at UCSF for Chronic Myeloid Leukemia focus on novel strategies including dose escalation of asciminib, HLA‑mismatched donor transplants, evaluation of treatment‑free remission after TKI cessation, and inhibition of nuclear export in leukemic cells.
This study highlights the ongoing difficulty of treating recurrent AML, underscoring the need for better therapies.
Bizonyítékszint: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Kapcsolódó jelek
- Can natural killer cells cure leukemia?
- Advancing Leukemia Diagnosis and Treatment: WHO-Supported Laboratory Innovations in Africa- A Narrative Review
- Immunotherapy for leukemia may change the bone marrow environment, cancer researchers find
- Next-generation CAR‑T therapy for acute myeloid leukemia: bridging innovation with clinical translation
- Chronic Myeloid Leukemia (CML): Background, Pathophysiology, Epidemiology